Google Scholar | Citations: 16429| h-index: 32 | i10-index: 482
Cutaneous polyarteritis nodosa: atypical presentation with gangrene
PDF (Portuguese (Brazil))

How to Cite

Cutaneous polyarteritis nodosa: atypical presentation with gangrene. (2020). Electronic Journal Collection Health, 51, e3323. https://doi.org/10.25248/reas.e3323.2020

Copyright © | All rights reserved.

The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.

Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.

Total reproduction
It is expressly prohibited and must be authorized by the journal.

Abstract

Objective: The purpose is to discuss this rare disease that demands high clinical suspicion, showing a severe presentation, comparison with other cases in the literature, form of treatment and clinical follow up. Case detail: A 60-year old woman, previously healthy, presented livedo reticularis, cutaneous ulcer and lower limb gangrene. Received steroid treatment, without resolution. She developed sepsis with cutaneous focus, contraindicating immunossupressant. Received plasmapheresis and immunoglobulin, with stabilization of the disease. However, the lower limbs had to be amputed. This report shows a rare and severe presentation of CPAN, with rapid progression to limb lower gangrene. Initially, aggressive clinical management was necessary, with corticosteroid therapy, without response. Alternative therapy with immunoglobulin and plasmapheresis, also suitable in the context of associated sepsis was administered. Treatment was effective for clinical control; however amputation of lower limbs was inevitable. Final considerations: Treatment initially involved corticosteroid therapy, but the patient developed sepsis with a cutaneous focus and progression of ischemia. Plasmapheresis and immunoglobulin were indicated, because of their safety in the infectious scenario. The patient evolved with clinical stabilization, and was followed with immunopression with prednisone, and Azatioprine for 1 year, without reccurence.

PDF (Portuguese (Brazil))